Clark Capital Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Clark Capital Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-568,676	Closed	-$14.1M	–	556
2026 Q1	$14.1M	Buy	+568,676	New	+$13.5M	0.09%	165
2025 Q3	–	Sell	-392,368	Closed	-$8.51M	–	449
2025 Q2	$8.51M	Buy	392,368 +147,373	+60%	+$3.48M	0.06%	165
2025 Q1	$5.94M	Buy	244,995 +37,262	+18%	+$839K	0.04%	178
2024 Q4	$4.34M	Buy	+207,733	New	+$4.46M	0.03%	206
2024 Q1	–	Sell	-173,858	Closed	-$2.92M	–	396
2023 Q4	$2.92M	Sell	173,858 -25,211	-13%	-$345K	0.02%	206
2023 Q3	$2.33M	Buy	199,069 +45,977	+30%	+$615K	0.02%	205
2023 Q2	$2.06M	Buy	153,092 +10,643	+7%	+$153K	0.02%	215
2023 Q1	$2.36M	Buy	+142,449	New	+$2.35M	0.03%	198

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clark Capital Management Group's CPRX Position: Q2 2026 in Review

Clark Capital Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 568,676 shares — an estimated $14.1M sold.

Clark Capital Management Group first reported a position in CPRX in Q1 2023 and held it in 8 quarters. The position peaked at $14.1M in Q1 2026. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Clark Capital Management Group reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Clark Capital Management Group sold 568,676 Catalyst Pharmaceutical shares in Q2 2026, an estimated $14.1M.
Clark Capital Management Group first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 8 quarters.
Clark Capital Management Group's Catalyst Pharmaceutical position peaked at $14.1M in Q1 2026.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.